ClexBio
Research - Oslo, Oslo, Norway
ClexBio Details
ClexBio is developing next-generation tissue engineering technology. We are an early-stage company with a breakthrough proprietary technology platform for scalable, high-throughput tissue generation. We have previously raised a $1.2M Seed round and $3.1M in non-dilutive grants. Our team brings highly relevant experience from the biotech industry and expertise in cell biology, tissue culture automation, and translational research from the Harvard Weitz Lab, Yale University, the Wake Forest Institute for Regenerative Tissue Engineering, Weill Cornell Medical College, and Zimmer Biomet.ClexBio owns the patents for a highly innovative method for creating biocompatible hydrogels as well as the technology to grow large tissues from healthy human cells in complex geometric shapes. We offer a radically different approach that enables scalable manufacturing of biocompatible & allogeneic grafts that are (i) available off-the-shelf and (ii) after implantation, will be repopulated by the patient's own cells - rebuilding & regenerating damaged tissues in the patient's body.As the first application of our technology, we are developing off-the-shelf, transplant-ready vein grafts consisting of human extracellular matrix. These grafts will address chronic venous insufficiency (CVI), a medical condition affecting 2.5M US patients, responsible for $30B in annual healthcare costs, and with no current long-term treatment options. In the future, ClexBio's product pipeline will also cover other types of engineered tissues.If you would like to be a part of the journey, get in touch with us today.
ClexBio Technologies
Email Providers
Gmail
Load Balancers
Varnish
Other
Mobile Friendly
Hosting
Amazon AWS